CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Eli Lilly and 3M have stopped a clinical trial of their jointly developed genital herpes treatment Resiquimod because preliminary data showed that the drug was not effective, The Wall Street Journal reports. Earlier Phase II trials showed that the drug was safe and well-tolerated, but preliminary data from a Phase III human trial showed that the compound was not as effective as expected in prompting the immune system into attacking herpes virus in the body, in preventing herpes outbreaks, or in helping to prevent people carrying the virus from infecting others. The companies plan to further analyze the trial data to determine whether to conduct further studies of the compound.
From our Sponsors
Most Popular
Watch Now: Pride Today
Latest Stories
Military vet Gina Ortiz Jones becomes first lesbian elected mayor of San Antonio
June 09 2025 6:19 PM
Federal court rules 'gender ideology' funding ban likely unconstitutional
June 09 2025 5:35 PM
Log Cabin Republicans NYC to host Pride event at Trump Tower
June 09 2025 5:13 PM
Southern Baptists seek to ban porn, women pastors, and marriage equality
June 09 2025 4:12 PM
The untold story of Sally-Tom, who legally changed her gender in the 1860s
June 08 2025 6:00 AM